CUE: The Data’s In… Kind Of
Cue Biopharma (CUE) released preliminary Phase 1A data this morning. There are several incremental updates. Here are the key takeways…
CUE: Here Comes The Data?
Cue Biopharma (CUE) is set to present interim Phase 1 data for CUE-101, which could start a rally that ulimately sees shares rise to $150. Here’s why…
CUE Q1 Preview: Data Release And Share Surge Imminent?
Cue Biopharma (CUE) is set to report Q1 2020 results. Here are six reasons why I expect positive data to come imminently and why shares could rally to $150+
CUE: Why Shares Could Be Worth $150 Or More
Shares of Cue Biopharma (CUE) are up more than 100% from our entry. But I’m letting this winner ride, as four relevant biotech deals point to another 97% to 637% upside to current prices. Here are all the details…
CUE Q1 2019 Key Takeaways: Despite IR Misstep, On Track For Data-Rich, “Transformational” Year
Five key takeaways from Cue Biopharma’s Q1 2019 report, including the list of catalysts management believes will result in 2019 being a “transformational” year…
CUE: Major Milestone Met On Path to Immunotherapy Market Disruption
Here are three reasons why today’s FDA approval to enter the clinic with CUE-101 for HPV-associated cancers is significant, including two not so obvious reasons. Plus, a list of catalysts for 2019…